Atyr Pharma vs Celldex Therapeutics
Celldex Therapeutics is the larger business, with $1.5m of revenue in fiscal 2025 against $190,000 for Atyr Pharma (8.1 times as much). Atyr Pharma grew faster (-19.1% against -78.0%). Celldex Therapeutics kept more of each dollar of sales as profit: a net margin of -16748.0% against -39009.5%. Atyr Pharma carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Atyr PharmaATYR, 2025 | Celldex TherapeuticsCLDX, 2025 |
|---|---|---|
| Revenue | $190,000 | $1.5m |
| Revenue growth | -19.1% | -78.0% |
| Net income | −$74.1m | −$259m |
| Operating margin | -40856.3% | -18599.8% |
| Net margin | -39009.5% | -16748.0% |
| Return on equity | -107.8% | -40.6% |
| Free cash flow | −$62.1m | −$214m |
| Cash | $10.7m | $28.9m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 58 | 198 |
| Market value | $622m | $2.32bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 1 buys, 3 sales | 0 buys, 2 sales |